Starpharma Spends September quarter progressing DEP technology
- Starpharma (SPL) spent the September quarter progressing its DEP technology and signing a new research agreement
- In mid-August, the company signed a new DEP research agreement with MSD to design and synthesise a number of DEP dendrimer conjugates for MSD to test and characterise
- In September, SPL presented promising anti-tumour activity data in prostate cancer at the ESMO Congress
- The company burnt through $7.28 million in the quarter and invested $101,000 in its property, plant and equipment
- As of September 30, the platform had $42.71 million in total available funding, representing 5.9 quarters of use if spending levels remain the same
- Company shares are down 5.25 per cent to end the day trading at 54 cents
